Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H3J6
UPID:
MTRFR_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H3J6; Q8WUC6
Background:
The Mitochondrial Translation Release Factor in Rescue plays a crucial role in mitochondrial function by ensuring the accuracy of protein synthesis. It is part of a quality control pathway that responds to interruptions during elongation, working alongside MTRES1 to eject unfinished nascent chains and peptidyl transfer RNA from stalled ribosomes. This mechanism is vital for maintaining mitochondrial integrity and function.
Therapeutic significance:
Linked to diseases such as Combined oxidative phosphorylation deficiency 7 and Spastic paraplegia 55, autosomal recessive, understanding the role of this protein could open doors to potential therapeutic strategies. Its involvement in mitochondrial disease and neurodegenerative disorders highlights its potential as a target for therapeutic intervention.